Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial

References

• Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998; 24: 104–117.
   PubMed Web of Science ®Google Scholar
• Charcot JM. Sclerose des cordons lateraux de la moelle epiniere chez une femme hysterique atteinte de contracture permanente des quatre membres. Bull de la Societe Med des Hopit de Paris 1865: 24–35.
   Google Scholar
• Olivares L, Esteban ES, Alter M. Mexican ‘resistance’ to amyotrophic lateral sclerosis. Arch Neurol 1972; 27: 397–402.
   PubMedGoogle Scholar
• Rosati G, Pinna L, Granieri E et al. Studies on epidemiological, clinical and aetiological aspects of ALS disease in Sardinia, southern Italy. Acta Neurol Scand 1977; 55: 231–241.
   Google Scholar
• Brewis M, Poskanzer DC, Rolland C, Miller H. Neurological disease in an English city. Acta Neurol Scand 1966; 42 (Suppl 24): 1–89.
   PubMed Web of Science ®Google Scholar
• Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyo- trophic lateral sclerosis in Olmsted county, Minnesota. 1925–1998. Neurology 2002; 59: 280–282.
   Google Scholar
• Mandrioli J, Fagioli P, Merelli E, Sola P. The epidemiology of ALS in Modena, Italy. Neurology 2003; 60: 683–689.
   PubMed Web of Science ®Google Scholar
• Preux PM, Druet-Cabanac M, Couratier P et al. Estimation of the amyotrophic lateral sclerosis incidence by capture-recapture method in the Limousin region of France. J Clin Epidemiol 2000; 53: 1025–1029.
   Google Scholar
• Okumura H. Epidemiological and clinical patterns of Western Pacific amyotrophic lateral sclerosis (ALS) in Guam and sporadic ALS in Rochester, Minnesota, USA and Hokkaido, Japan. A comparative study. Hokkaido Igaku Zasshi 2003; 78: 187–195 (in Japanese.).
   Google Scholar
• Scottish Motor Neurone Disease Research Group. The Scottish motor neuron disease register: a prospective study of adult onset motor neuron disease in Scotland. Methodology, demo- graphics and clinical features of incidence cases in 1989. J Neurol Neurosurg Psychiatry 1992; 55: 536–541.
   Google Scholar
• Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995–1997: a population-based study. Neurology 1999; 52: 504–509.
   PubMed Web of Science ®Google Scholar
• Kondo K. Epidemiology of motor neuron disease. In: PN Leigh, M Swash, eds. Motor Neuron Disease: Biology and Manage- ment. Springer-Verlag, 1995: 19.
   Google Scholar
• Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci 2001; 191: 3–9.
   PubMed Web of Science ®Google Scholar
• Kurland LT, Mulder DW. Epidemiological investigations of amyotrophic lateral sclerosis: 1. Preliminary report on geogra- phical distribution, with special reference to the Mariana Islands, including clinical and pathological observations. Neurology 1954; 4: 355–378.
   Google Scholar
• Plato CC, Garruto RM, Fox KM, Gajdusek DC. Amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam: a 25- year prospective case-control study. Am J Epidemiol 1986; 124: 643–656.
   PubMed Web of Science ®Google Scholar
• Juergens SM, Kurland LT, Okazaki H, Mulder DW. ALS in Rochester, Minnesota, 1925–1977. Neurology 1980; 30: 463–470.
   PubMed Web of Science ®Google Scholar
• Durrleman S, Alperovitch A. Increasing trend of ALS in France and elsewhere: are the changes real? Neurology 1989; 39: 768–773.
   PubMed Web of Science ®Google Scholar
• Pavlovsky Z, Vagunda V. Apoptosis-selected methods of detection of apoptosis and associated regulatory factors on tissue sections of tumours. Cesk Patol 2003; 39: 6–10.
   PubMedGoogle Scholar
• Peng L, Jiang H, Bradley C. Annexin V for flow cytometric detection of phosphatidylserine expression on lymphoma cells undergoing apoptosis. Hua Xi Yi Ke Da Xue Bao 2001; 32: 602–604 (in Chinese.).
   Google Scholar
• Dupuis L, Gonzalez de Aguilar JL, di Scala F et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 358–365.
   Google Scholar
• Bromberg M. Accelerating the diagnosis of amyotrophic lateral sclerosis. Neurologist 1999; 5: 63–74.
   Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyo- trophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293–299.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Crump S, al-Sarraj S, Anderson V, Cavanagh J, Leigh PN. The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathological study. J Neurol Sci 1995; 129(Suppl): 11–12.
   Google Scholar
• Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi C. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 15–21.
   Google Scholar
• Househam E, Swash M. Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement? J Neurol Sci 2000; 180: 76–81.
   PubMed Web of Science ®Google Scholar
• Riviere M, Meninger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998; 55: 526–528.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Leigh PN. Recent advances in amyotrophic lateral sclerosis. Curr Opin Neurol 2000; 13: 397–405.
   PubMedGoogle Scholar
• Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688–1700.
   PubMed Web of Science ®Google Scholar
• Shaw CE, Al Chalabi A, Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 2001; 1: 69–76.
   PubMedGoogle Scholar
• Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806–819.
   PubMed Web of Science ®Google Scholar
• Robertson J, Kriz J, Nguyen MD, Julien JP. Pathways to motor neuron degeneration in transgenic mouse models. Biochimie 2002; 84: 1151–1160.
   PubMed Web of Science ®Google Scholar
• Julien JP, Beaulieu JM. Cytoskeletal abnormalities in amyo- trophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci 2000; 180: 7–14.
   PubMed Web of Science ®Google Scholar
• Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999; 58: 459–471.
   PubMed Web of Science ®Google Scholar
• Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol 2001; 27: 257–274.
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyo- trophic lateral sclerosis. Nature 1993; 362: 59–62.
   Google Scholar
• Shaw CE, Enayat ZE, Chioza BA et al. Mutations in all five exons of SOD-1 may cause ALS. Ann Neurol 1998; 43: 390–394.
   Google Scholar
• Yang Y, Hentati A, Deng HX et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001; 29: 160–165.
   Google Scholar
• LaMonte BH, Wallace KE, Holloway BA et al. Disruption of dynein/ dynactin inhibits axonal transport in motor neurons causing late- onset progressive degeneration. Neuron 2002; 34: 715–27.
   Google Scholar
• Puls I, Jonnakuty C, LaMonte BH et al. Mutant dynactin in motor neuron disease. Nat Genet 2003; 33: 455–456.
   Google Scholar
• Al-Chalabi A, Andersen PM, Nilsson P et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8: 157–164.
   Google Scholar
• Robertson J, Doroudchi MM, Nguyen MD et al. A neurotoxic peripherin slice variant in a mouse model of ALS. J Cell Biol 2003; 160: 939–949.
   Google Scholar
• Meyer T, Alber B, Roemer K et al. High rate of constitutional chromosomal rearrangements in apparently sporadic ALS. Neurology 2003; 60: 1348–1350.
   Google Scholar
• Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. New Engl J Med 2003; 348: 1365–1375.
   PubMed Web of Science ®Google Scholar
• Mattson M. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med 2003; 3: 65–94.
   PubMed Web of Science ®Google Scholar
• Guegan C, Przedborski S. Programmed cell death in amyo- trophic lateral sclerosis. J Clin Invest 2003; 111: 153–161.
   PubMed Web of Science ®Google Scholar
• Przedborski S, Clarke PGH. Cell death pathways in amyo- trophic lateral sclerosis. In: Shaw PJ, Strong MJ, eds. Blue Series. Motor Neuron Disorders. New York: Elsevier Science, 2003:357–377.
   Google Scholar
• Martin LJ. Neuronal cell death in nervous system development, disease and injury. Int J Mol Med 2001; 7: 455–478.
   PubMed Web of Science ®Google Scholar
• Vila M, Przedborski S. Targeting programmed cell death in neurodegeneative diseases. Nat Rev Neurosci 2003; 4: 365–375.
   PubMed Web of Science ®Google Scholar
• Heath AM, Shaw PJ. Update on the glutamatergic neurotrans- mitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002; 26: 438–458.
   PubMed Web of Science ®Google Scholar
• Rizzardini M, Lupi M, Bernasconi S, Mangolini A, Cantoni L. Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid. J Neurol Sci 2003; 207: 51–58.
   PubMed Web of Science ®Google Scholar
• Waldmeier PC. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 303–321.
   PubMed Web of Science ®Google Scholar
• Deng H-X, Siddique T. Transgenic mouse models and human neurodegenerative disorders. Arch Neurol 2000; 57: 1695–1702.
   PubMedGoogle Scholar
• Gurney ME, Cutting FB, Zhai P et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147–157.
   Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5: 347–350.
   Google Scholar
• Desnuelle C, Dib M, Garrel C, Favier A et al. A double-blind, placebo controlled randomised clinical trial of alpha- tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-tocopherol Study Group. Amyotroph Lat Scler Other Motor Neuron Disord 2001; 2: 9–18.
   Google Scholar
• Miller RG, Moore DH, Gelinas DF et al. Phase III randomised trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843–848.
   Google Scholar
• Groeneveld GJ, Veldink JH, van der Tweel I et al. A randomised sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–445.
   Google Scholar
• Shibata N. Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Neuro- pathol 2001; 21: 82–92.
   Google Scholar
• Lai EC, Felice KJ, Festoff BW et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo controlled study. The North America ALS/IGF-I Study Group. Neurology 1997; 49: 1621–1630.
   Google Scholar
• Borasio GD, Robberecht W, Leigh PN et al. A placebo controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998; 51: 583–586.
   Google Scholar
• BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 1999; 52: 1427–1433.
   PubMed Web of Science ®Google Scholar
• ALS CNTF Treatment Study Group. A double-blind placebo controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 1996; 46: 1244–1249.
   Google Scholar
• Miller RG, Bryan WW, Dietz MA et al. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology 1996; 47: 1329–1331.
   Google Scholar
• Miller RG, Moore D, Young LA et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996; 47: 1383–1388.
   Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group [see comments]. N Engl J Med 1994; 330: 585–591.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II [see comments]. Lancet 1996; 347: 1425–1431.
   Google Scholar
• Sanofi-Synthelabo Inc. Data on file.
   Google Scholar
• Cudkowicz M. Clinical trial of topiramate in subjects with amyotrophic lateral sclerosis. Presented at 13th international symposium on ALS/MND, Melbourne, Australia, 17–19 November 2002, C29.
   Google Scholar
• Drory VE, Gross D. No effect of creatine on respiratory distress in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 43–46.
   PubMed Web of Science ®Google Scholar
• Savas S, Delibas N, Savas C, Sutcu R, Cindas A. Pentoxifylline reduces biochemical markers of ischaemia-reperfusion induced spinal cord injury in rabbits. Spinal Cord 2002; 40: 224–229.
   PubMed Web of Science ®Google Scholar
• Tateishi N, Mori T, Kagamiishi Y et al. Astrocytic activation and delayed infarct expansion after permanent focal ischaemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurological deficits. J Cereb Blood Flow Metab 2002; 22: 723–734.
   Google Scholar
• Zhu S, Stavrovskaya IG, Drozda M et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417: 74–78.
   Google Scholar
• Kriz J, Nguyen M, Julien J. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 268.
   PubMed Web of Science ®Google Scholar
• Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002; 13: 1067–1070.
   PubMed Web of Science ®Google Scholar
• Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999; 386: 735–767.
   Google Scholar
• Jain KK. Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs 2000; 9: 1397–1406.
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Araujo DM, Song D, Zivin JA. Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioural deficits induced by reversible spinal cord ischaemia. Stroke 2001; 32: 1220–1225.
   PubMed Web of Science ®Google Scholar
• Sagot Y, Toni N, Perrelet D et al. An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motor neuron disease. Br J Pharmacol 2000; 131: 721–728.
   Google Scholar
• Bourke SC, Shaw PJ, Gibson GJ. Respiratory function vs. sleep- disordered breathing as predictors of QOL in ALS. Neurology 2001; 57: 2040–2044.
   Google Scholar
• Lechtzin N, Rothstein J, Clawson L, Diette GB, Wiener CM. Amyotrophic lateral sclerosis: evaluation and treatment of respiratory impairment. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 5–13.
   PubMed Web of Science ®Google Scholar
• Jackson CE, Rosenfeld J, Moore DH et al. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci 2001; 191: 75–78.
   Google Scholar
• Lou JS, Reeves A, Benice T, Sexton G. Fatigue and depression are associated with poor quality of life in ALS. Neurology 2003; 60: 122–123.
   PubMed Web of Science ®Google Scholar
• Newsom-Davis IC, Lyall RA, Leigh PN et al. The effect of non- invasive positive pressure ventilation (NIPPV) on cognitive function in amyotrophic lateral sclerosis (ALS): a prospective study. J Neurol Neurosurg Psychiatry 2001; 71: 482–487.
   Google Scholar
• Lyall RA, Donaldson N, Fleming T et al. A prospective study of quality of life in ALS patients treated with non-invasive ventilation. Neurology 2001; 57: 153–156.
   Google Scholar
• Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in amyo- trophic lateral sclerosis. Brain 2001; 124(Pt 10): 2000–2013.
   Web of Science ®Google Scholar
• ALS CNTF treatment study (ACTS) Phase I-II Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assess- ment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996; 53: 141–147.
   Google Scholar
• Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996; 47(Suppl 4): S233–241.
   Google Scholar
• Mitsumoto H, Salgado ED, Negroski D et al. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology 1986; 36: 152–159.
   Google Scholar
• Abe K, Takanashi M, Watanabe Y et al. Decrease in N- acetylaspartate/creatine ratio in the motor area and the frontal lobe in amyotrophic lateral sclerosis. Neuroradiology 2001; 43: 537–541.
   Google Scholar
• de Carvalho M, Turkman A, Swash M. Motor responses evoked by transcranial magnetic stimulation and peripheral nerve stimulation in the ulnar innervation in amyotrophic lateral sclerosis; the effect of upper and lower motor neuron lesion. J Neurol Sci 2003; 210: 83–90.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Gooch CL. Motor unit number estimation in neurological disease. Adv Neurol 2002; 88: 33–52.
   PubMedGoogle Scholar
• Olney RK. Motor unit number estimation (MUNE). Amyotroph Lat Scler 2002; 3(Suppl 1): S91–92.
   Google Scholar
• Eisen A, Swash M. Clinical neurophysiology of ALS. Clin Neurophysiol 2001; 112: 2190–2201.
   PubMed Web of Science ®Google Scholar
• Piantadosi S. Clinical trials: a methodolgical perspective. John Wiley, New York 1997.
   Google Scholar
• Gordon H, Miller RG, Moore DH. ALSFRS-R as a primary outcome measure in amyotrophic lateral sclerosis clinical trials. ALS Other Motor Neuron Disord 2003. (in press.)
   Google Scholar
• Magnus T, Beck M, Giess R, Puis I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002; 25: 709–714.
   PubMed Web of Science ®Google Scholar
• Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology 1993; 43: 246–70.
   Google Scholar
• Miller R, Mitchell J, Moore D. Riluzole for amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). Cochrane Library, Oxford. Issue 2, 2003.
   Google Scholar
• Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987; 22: 328–333.
   PubMed Web of Science ®Google Scholar
• Sanjak M, Salachas F, FrijaOrvoen E et al. Prospective quality control of vital capacity as primary endpoint in international multicentre therapeutic trial of SR57746A (xaliproden) in amyotrophic lateral sclerosis. Ann Neurol 2000; 48: 274.
   Google Scholar
• Coulthard-Morris L, Burks JS, Herndon RM. Rehabilitation Outcome Measures. In: Herndon RM, ed. Handbook of Neurologic Rating Scales. Demos Vermande 1997: 225–264.
   Google Scholar
• McGuire D, Garrison L, Armon C et al. A brief quality- of-life measure for ALS clinical trials based on a subset of items from the Sickness Impact Profile. The Syntex-Synergen ALS/CNTF Study Group. J Neurol Sci 1997; 152(Suppl 1): S18–22.
   Google Scholar
• Jenkinson C, Peto V, Jones G, Fitzpatrick R. Interpreting change in scores on the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40). Clin Rehabil 2003; 17: 380–385.
   PubMed Web of Science ®Google Scholar
• Eisen A, Krieger C. ALS therapy, therapeutic trials, and neuro- protection. Amyotrophic Lateral Sclerosis - A Synthesis of Research and Clinical Practice. Cambridge University Press, 1998: 209–237.
   Google Scholar
• Bromberg MB, Anderson F, Davidson M, Miller RG. Assessing health status quality of life in ALS: comparison of the SIP/ALS-19 with the ALS Functional Rating Scale and the Short Form-12 Health Survey. ALS CARE Study Group. Clinical Assessment, Research, and Education. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 31–37.
   Google Scholar
• Jenkinson C, Fitzpatrick R, Swash M, Peto V. The ALS Health Profile Study: quality of life of amyotrophic lateral sclerosis patients and carers in Europe. J Neurol 2000; 247: 835–840.
   PubMed Web of Science ®Google Scholar
• Robbins RA, Simmons Z, Bremer BA, Walsh SM, Fischer S. Quality of life in ALS is maintained as physical function declines. Neurology 2001; 56: 442–444.
   PubMed Web of Science ®Google Scholar
• Norris FH Jr, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974; 24: 721–728.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assess- ments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13–21.
   Google Scholar
• Sorenson EJ, Barkhaus PE, Davis W et al. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology, 2003 (in press.)
   Google Scholar
• Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805.
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neuron disease: the ALSAQ-40. J Neurol 1999; 246(Suppl 3): 16–21.
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Fitzpatrick R. Reduced item set for the amyo- trophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5. J Neurol Neurosurg Psychiatry 2001; 70: 70–73.
   PubMed Web of Science ®Google Scholar
• Hickey AM, Bury G, O’Boyle CA, Bradley F, O’Kelly FD, Shannon W. A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS. BMJ 1996; 313: 29–33.
   PubMed Web of Science ®Google Scholar
• Munsat TL. Slowing down ALS – is this good or bad? Amyo- troph Lateral Scler Other Motor Neuron Disord 2001; 2(Suppl 1): S19–22.
   PubMedGoogle Scholar
• Moore DH, Miller RGthe Western ALS Study Group. Improving efficiency of ALS Clinical Trials. (12th International Symposium on ALS/MND). Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 20.
   Google Scholar
• Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS; World Federation of Neurology Research Committee on Motor Neuron Diseases. J Neurol Sci 1999; 169: 2–12.
   PubMed Web of Science ®Google Scholar